Robert W. Yeh et al. JACC 2017;70:

Slides:

Advertisements

Similar presentations

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

PRODIGY Objective Study Design Primary Composite Endpoint

Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study Robert W. Yeh,

Embargoed Until 10:45 a.m. ET, Tuesday, Nov. 10, 2015

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Discontinuation of medication after nonfatal event: MI

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Figure 1 Ischaemic endpoints

Volume 55, Issue 3, Pages (May 2010)

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Circ Cardiovasc Interv

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

American College of Cardiology Presented by Dr. Stephan Windecker

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Dean J. Kereiakes et al. JACC 2017;70:

Jun M, et al. Lancet 2010 Epub May 10

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

The American College of Cardiology Presented by Dr. Raimund Erbel

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

American Heart Association Presented by Dr. Julinda Mehilli

Potential conflicts of interest

On behalf of all principal COMPARE II investigators:

John A. Bittl et al. JACC 2016;68:

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Flow of Patients Through Trial

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Seung-Yul Lee et al. JCIN 2018;j.jcin

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Giuseppe Gargiulo et al. JACC 2018;71:

Glenn N. Levine et al. JACC 2011;58:e44-e122

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Stavros V. Konstantinides et al. JACC 2017;69:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Christian Madelaire et al. JCHF 2018;6:

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Pamela E. Scott et al. JACC 2018;71:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Robert W. Yeh et al. JACC 2017;70:2213-2223 Dual Antiplatelet Therapy With Complex Lesions: Cumulative Incidence of Endpoint Events From 12 to 30 Months After Randomization The endpoint events were stratified by randomized treatment arm and number of anatomical complexity characteristics. Outcomes were analyzed comparing randomized treatments among subgroups of subjects with 0 (n = 7,824), 1 (n = 3,182), or 2 or more (n = 548) anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors. Relative treatment effects were consistent for the outcomes of MI or stent thrombosis and MACCE independent of the number of complexity characteristics. MACCE = major adverse cardiovascular or cerebrovascular event(s); MI = myocardial infarction. Robert W. Yeh et al. JACC 2017;70:2213-2223 2017 American College of Cardiology Foundation